ACR – EULAR Classification Criteria for Systemic Sclerosis May 25, 2013 Sindhu Johnson MD PhD.

Slides:



Advertisements
Similar presentations
ASSESSING RESPONSIVENESS OF HEALTH MEASUREMENTS. Link validity & reliability testing to purpose of the measure Some examples: In a diagnostic instrument,
Advertisements

Coinvolgimento polmonare nella sclerosi sistemica Marco Matucci Cerinic Departments of Rheumatology AVC BioMedicine & Division of Rheumatology AOUC Medicine,
Virginia Steen, MD Professor of Medicine
Calcinosis Working Group Update SCTC Business Meeting ACR October 26, 2013 Lorinda Chung.
CREST J. Ryan Altman, MD AM REPORT 9 December 2009.
Group Techniques John A. Cagle California State University, Fresno.
ACR/EULAR Classification Criteria for Systemic Sclerosis (SSc, Scleroderma) © 2013 ACR / EULAR.
First International Psoriatic Arthritis Working Group Meeting: 8/15-17/03 NYC Philip Mease MD.
Decision-Making Understand the main steps involved in rational decision-making Discuss the major reasons for poor decisions, and describe what managers.
EVALUATION OVERVIEW: Key Questions and Roles Mary L. Fennell, Ph.D. (EOC Chair) Professor and Chair, Brown University June 19, 2007.
MEASUREMENT. Measurement “If you can’t measure it, you can’t manage it.” Bob Donath, Consultant.
IMACS History and Development of Myositis Clinical Trials Muscle Study Group September 21, 2010 Chester V. Oddis, MD University of Pittsburgh.
Prevalence of PAH in SSc ReferenceMethodologyDiagnosisPAH prevalence Mukerjee; 2003, UK n = 722, single center Prospective RHC12%
Early detection of pulmonary involvement in scleroderma patients By Mohamed Mostafa Metwally, MD, FCCP Assistant professor of chest diseases Assiut University.
The Impact of IMMPACT Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia and Rheumatology Products Center for Drug Evaluation and Research.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Assessing person-centredness: the Person-centred Practice Index by Dr Paul Slater.
Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative van.
Mosby items and derived items © 2005 by Mosby, Inc. Chapter 20 Managing Client Care.
VASCULAR COMPLICATIONS OF SYSTEMIC SCLEROSIS Future Directions in Treatment of Systemic Sclerotic Complications Janet Pope, MD Professor Division of Rheumatology.
McGraw-Hill/Irwin Business Research Methods, 10eCopyright © 2008 by The McGraw-Hill Companies, Inc. All Rights Reserved. Chapter 11 Measurement.
Scleroderma Renal Crisis
VASCULAR COMPLICATIONS OF SYSTEMIC SCLEROSIS Early Diagnosis of PAH in Systemic Sclerosis: How Do We Recognize the Warning Signs? Joseph C. Shanahan, MD.
Making Sense of What we Read about Scleroderma Treatments Kimberly Watkinson September 19, 2014.
Wednesday, November 15, 2006 Washington, DC Richard M. Silver, MD, Program Chair VASCULAR COMPLICATIONS OF SYSTEMIC SCLEROSIS.
Author: Cumurciuc Mihai Co-author:Silvia Ioana Morar Coordinator: Dr. Parvu Mirela.
CURRENT PRACTICES FOR DATA COLLECTION & DECISION ANALYSIS Session Moderator: Robert E. Lee, Jr. Chair, PhRMA Trademark Subcommittee.
Undifferentiated Connective Tissue Disease (What is the relationship between UCTD and SLE?) R. John Looney, MD Stephen and Elise Rosenfeld Distinguished.
Validation and Refinement of a Prediction Rule to Identify Children at Low Risk for Acute Appendicitis Kharbanda AB, Dudley NC, Bajaj L, et al; Pediatric.
12-1 Chapter 12 Measurement Learning Objectives Understand... distinction between measuring objects, properties, and indicants of properties similarities.
McGraw-Hill/IrwinCopyright © 2014 by The McGraw-Hill Companies, Inc. All rights reserved. MEASUREMENT Chapter 11.
CLINICAL MANIFESTATION OF SYSTEMIC SCLEROSIS
Co-chairs: Mandy Nikpour (Melbourne) and Murray Baron (Montreal) SCTC Annual Business Meeting, Saturday November 15 th 2014.
Date of download: 6/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Historical criteria that distinguish syncope from.
Autoantibodies associated with Rheumatic disease
2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative An.
Scleroderma Lung Disease Robert Schilz DO, PhD University Hospitals Case Medical Center Cleveland, OH.
Scleroderma Lab Data and Diagnosis Iraj Salehi-Abari MD., Internist
Scleroderma Raynaud’s phenomenon Iraj Salehi-Abari MD., Internist
Fig 1: Skin thickening and sclerodactyly Fig 2: Digital tip ulcers
Volume 120, Issue 1, Pages S66-S68 (July 2001)
EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD)
2015 Gout Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative Tuhina Neogi,1 Tim.
‘RETROSPECTIVE STUDY OF EFFICACY OF I. V
pSS: primary SS; Scl: scleroderma.
Systemic Sclerosis Criteria.
Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1
Management of Spontaneous Pneumothorax
EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD) V. Smith*1, A. Herrick2, A. Sulli3 and M. Cutolo3 1Ghent University Hospital, University.
Figure 1 Historical evolution of the clinical classification and
Improving the Recognition and Diagnosis of Fibromyalgia
Management of Spontaneous Pneumothorax
Case Collection in RA: Highlights of an Interactive Workshop
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
Skin-Resident Effector Memory CD8+CD28– T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis  Gang Li, Adriana T. Larregina, Robyn.
A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis  Lorinda Chung, MD, David Fiorentino,
Systemic sclerosis (SSc; also known as scleroderma) is a complex connective tissue disease (CTD) of unknown etiology. It is characterized by fibrotic.
Anil Vachani, MD, Harvey I. Pass, MD, William N. Rom, MD, David E
Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.
The Patient Experience: Patient-Reported Outcomes in Rheumatology
The peptide arrays stained with ...
Near-infrared spectroscopy: What we know and what we need to know—A systematic review of the congenital heart disease literature  Jennifer C. Hirsch,
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Clinical response in patients with early and established RA at month 24. *p
How to Screen for PAH in Scleroderma-Spectrum Disorders
ACR20/50/70 response rates at week 24 (TP1 per-protocol set).
Projects with publication Courses, meetings and presentations in 2018
EULAR Study Group: Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatology Aim of the study group To understand the required clinical and economic.
ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.
Presentation transcript:

ACR – EULAR Classification Criteria for Systemic Sclerosis May 25, 2013 Sindhu Johnson MD PhD

Highlight the limitations of pre-existing classification criteria To discuss the development of the new classification criteria To discuss the application of the 2013 classification criteria 2 Learning Objectives

American College of Rheumatology Classification and Response Criteria Subcommittee of the Committee on Quality Measures. Disclosures

Co-convenors Janet Pope Frank van den Hoogen Members Jaap Fransen Sindhu Johnson Alan Tyndall Murray Baron Marco Matucci-Cerinic Dinesh Khanna Collaborators Ray Naden Christopher Denton Oliver Distler Armando Gabrielli Jaap van Laar Maureen Mayes Virginia Steen James Seibold Phillip Clements Thomas Medsger Gabriela Riemekasten Patricia Carreira Collaborators Lorinda Chung Barri Fessler Peter Merkel Richard Silver John Varga Yannick Allanore Ulf Mueller-Ladner Madelon Vonk Ulrich Walker Susanna Cappelli

SSc diagnosis SSc classification

Major criterion * Proximal scleroderma Minor criteria * Sclerodactyly * Digital pitting or scars or loss of substance from finger pad * Bibasilar pulmonary fibrosis Major criterion or 2 minor criteria ACR Preliminary Classification Criteria for Systemic Sclerosis Arthritis Rheum 1980; 23:581-90

Sensitivity 97% of definite SSc cases Specificity 98% the comparison patients 1 major criterion or ≥ 2 minor criteria ACR Preliminary Classification Criteria for Systemic Sclerosis Arthritis Rheum 1980; 23:581-90

Classification schemes – Overview – American College of Rheumatology 1988 – LeRoy: lcSSc and dcSSc 2001 – LeRoy: lSSc

Limited cutaneous SSc Early SSc New knowledge Nailfold capillaries SSc- specific antibodies Limitations of ACR classification criteria for SSc. Miss subsets SSc diagnosis SSc classification 20%

Collaboration between experts and clinical epidemiologists Evaluate psychometric properties of candidate criteria Balance of expert based and data driven methods Avoid circularity of reasoning

Classification schemes – Overview Current: ACR-EULAR Collaboration – American College of Rheumatology 1988 – LeRoy: lcSSc and dcSSc 2001 – LeRoy: lSSc

Item Generation (Delphi panel) N = 168 Item Reduction (Delphi panel followed by Nominal Group Technique) N = 23 Evaluate validity of items in SSc and SSc mimickers Collect prospective data in SSc and SSc mimickers Consensus Method Data-Driven Method Evaluate operating characteristics of SSc criteria Item reduction, weighting & scaling

Entry Criterion ? meets “Threshold” Multi-Criteria Decision Analysis Absolute Criteria Exclusion Criteria NO Not Systemic Sclerosis Systemic Sclerosis YES NO YES

Derivation sample (N=200) Validation sample (N=405) Validation sample ≤ 3 years disease duration (N=100) Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) 1980 ARA SSc Criteria 0.80 (0.72, 0.87) 0.77 (0.68, 0.84) 0.75 (0.70, 0.80) 0.72 (0.64, 0.79) 0.75 (0.70, 0.80) 0.72 (0.63, 0.79) 2001 LeRoy and Medsger criteria 0.76 (0.68, 0.84) 0.69 (0.68, 0.84) 0.75 (0.70, 0.80) 0.78 (0.70, 0.85) 0.80 (0.69, 0.88) 0.76 (0.53, 0.92) 2013 ACR-EULAR SSc Classification Criteria 0.95 (0.90, 0.98) 0.93 (0.86, 0.97) 0.91 (0.87, 0.94) 0.92 (0.86, 0.96) 0.91 (0.83, 0.96) 0.90 (0.70, 0.99)

Highlight the limitations of pre-existing classification criteria To discuss the development of the new classification criteria To discuss the application of the 2013 classification criteria 19 Learning Objectives